Gsa Capital Partners LLP Actinium Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$4.57 - $6.4 $258,995 - $362,707	-56,673 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$6.01 - $8.8 $69,307 - $101,481	-11,532 Reduced 16.91%	56,673 $341,000
Q3 2021 Nov 12, 2021	BUY	$5.76 - $9.67 $121,582 - $204,114	21,108 Added 44.82%	68,205 $604,000
Q2 2021 Aug 05, 2021	BUY	$7.01 - $8.63 $56,717 - $69,825	8,091 Added 20.74%	47,097 $373,000
Q1 2021 May 10, 2021	BUY	$7.62 - $9.79 $297,225 - $381,868	39,006 New	39,006 $297,000
Q4 2020 Feb 03, 2021	SELL	$7.8 - $12.64 $107,819 - $174,722	-13,823 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$7.26 - $18.0 $100,354 - $248,814	13,823 New	13,823 $134,000

7.05M

96.6K

70.5K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $45.3M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.